Participant flow

Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma · Source last updated 2016-12-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Patients receive celecoxib PO BID for 6 months in the absence of unacceptable toxicity or progression to malignancy.

   id

   FG000

   title

   Arm I (Celecoxib)

2. description

   Patients receive placebo PO BID for 6 months in the absence of unacceptable toxicity or progression to malignancy.

   id

   FG001

   title

   Arm II (Placebo)

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         11

      2. group Id

         FG001

         num Subjects

         12

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         11

      2. group Id

         FG001

         num Subjects

         12

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

pre Assignment Details

There were no significant events or approaches utilized following enrollment but prior to group assignment.

recruitment Details

23 asymptomatic adult patients with a serum monoclonal protein \>1g/dL from Cleveland Clinic, Mayo Clinic, or University of Arkansas Medical Center were randomized between August 2005 and April 2008

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice